Export financials
Hutchison China MediTech Limited (HCM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Hutchison China MediTech Limited Financial Statements 2025-2011 | HCM
Annual Financial Statements Hutchison China MediTech Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
12 B | 12.8 B | 12.8 B | 11.3 B | 21.6 B | 20.1 B | 15.5 B | 17.3 B | 20.8 B | 843 M | - | - | - | - | - |
Shares |
858 M | 855 M | 850 M | 847 M | 793 M | 698 M | 666 M | 664 M | 617 M | 59.7 M | - | - | - | - | - |
Historical Prices |
14 | 15 | 15.1 | 13.3 | 27.2 | 28.7 | 23.3 | 26.1 | 33.7 | 12.7 | - | - | - | - | - |
Net Income |
457 M | 37.7 M | 101 M | -361 M | -195 M | -126 M | -106 M | -74.8 M | -26.7 M | -43 M | 7.99 M | 5.37 M | 5.92 M | 3.64 M | 710 K |
Revenue |
549 M | 630 M | 838 M | 426 M | 356 M | 228 M | 205 M | 214 M | 241 M | 216 M | 178 M | 91.8 M | 46 M | 195 M | 167 M |
Cost of Revenue |
336 M | 349 M | 384 M | 311 M | 91.6 M | 63.5 M | 46.2 M | 35.3 M | 24.8 M | 21.7 M | 17.3 M | - | - | - | - |
Gross Profit |
- | - | - | - | - | 39.5 M | 205 M | 214 M | 241 M | 216 M | 67.4 M | 19.8 M | 23.8 M | 96 M | 92.8 M |
Operating Income |
-39.2 M | -43.7 M | 18.4 M | -408 M | -328 M | -197 M | -146 M | -92.6 M | -53.4 M | -46.7 M | -9.77 M | -18.3 M | - | - | - |
Interest Expense |
- | - | 759 K | 652 K | 592 K | 787 K | 1.03 M | 1.01 M | 1.46 M | 1.63 M | 1.4 M | 1.52 M | - | - | - |
EBITDA |
-25.9 M | -31.4 M | 26.6 M | -399 M | -321 M | -191 M | -141 M | -89.1 M | -50.8 M | -46.7 M | -7.76 M | -5.92 M | -87 K | 2.64 M | 9.91 M |
Operating Expenses |
- | - | - | - | - | 236 M | 190 M | 163 M | 119 M | 106 M | 77.2 M | 26.9 M | 24.8 M | 97.4 M | 87.2 M |
General and Administrative Expenses |
66.7 M | 64.3 M | 79.8 M | 92.2 M | 89.3 M | 50 M | 39.2 M | 30.9 M | 24 M | - | 19.6 M | 22.6 M | 21.3 M | 35.7 M | - |
All numbers in USD currency
Quarterly Income Statement Hutchison China MediTech Limited
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
858 M | 857 M | 855 M | 856 M | 850 M | 847 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 665 M | - | - | - | 664 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
457 M | 455 M | 37.7 M | 25.8 M | 101 M | 169 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.9 M | - | - | - | -11.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
549 M | 278 M | 630 M | 306 M | 838 M | 533 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 52.2 M | - | - | - | 52.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
336 M | 168 M | 349 M | 36.9 M | 384 M | 45.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.3 M | - | - | - | 7.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-39.2 M | -3.51 M | -43.7 M | -27.5 M | 18.4 M | 112 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -36 M | - | - | - | -25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | 21.6 M | - | 1.48 M | 759 K | 224 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 260 K | - | - | - | 206 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-25.9 M | 2.6 M | -31.4 M | -21.3 M | 26.6 M | 115 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.8 M | - | - | - | -24.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
66.7 M | 27.8 M | 64.3 M | 30.5 M | 79.8 M | 41.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.2 M | - | - | - | 7.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Main types of financial statements Hutchison China MediTech Limited HCMFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Hutchison China MediTech Limited plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
BridgeBio Pharma
BBIO
|
$ 66.14 | 0.51 % | $ 12.7 B | ||
|
BioCardia
BCDA
|
$ 1.09 | 4.81 % | $ 7.27 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
$ 8.1 | 0.31 % | $ 1.7 B | ||
|
Bicycle Therapeutics plc
BCYC
|
$ 4.01 | 18.64 % | $ 278 M | ||
|
Black Diamond Therapeutics
BDTX
|
$ 1.94 | 2.65 % | $ 110 M | ||
|
Beam Therapeutics
BEAM
|
$ 25.67 | 4.78 % | $ 2.54 B | ||
|
Biogen
BIIB
|
$ 223.59 | 1.69 % | $ 32.8 B | ||
|
BioVie
BIVI
|
$ 1.44 | 0.68 % | $ 2.13 M | ||
|
BioLineRx Ltd.
BLRX
|
$ 2.32 | 0.43 % | $ 5.72 B | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 57.54 | 0.63 % | $ 11 B | ||
|
Bristol-Myers Squibb Company
BMY
|
$ 58.81 | 0.53 % | $ 120 B | ||
|
Benitec Biopharma
BNTC
|
$ 9.23 | 2.78 % | $ 430 M | ||
|
BioNTech SE
BNTX
|
$ 97.64 | 0.76 % | $ 23.6 B | ||
|
Burford Capital Limited
BUR
|
$ 3.55 | 0.51 % | $ 778 M | ||
|
BeyondSpring
BYSI
|
$ 0.79 | 2.12 % | $ 32.5 M | ||
|
Cabaletta Bio
CABA
|
$ 2.08 | 4.0 % | $ 209 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 2.14 | 0.45 % | $ 3.52 M | ||
|
Capricor Therapeutics
CAPR
|
$ 7.78 | 0.11 % | $ 362 M | ||
|
Catalyst Biosciences
CBIO
|
$ 13.94 | 0.42 % | $ 1.25 B | ||
|
C4 Therapeutics
CCCC
|
$ 2.99 | 1.36 % | $ 248 M | ||
|
Codexis
CDXS
|
$ 1.39 | 2.21 % | $ 121 M | ||
|
Cerus Corporation
CERS
|
$ 2.34 | 2.63 % | $ 446 M | ||
|
Certara
CERT
|
$ 10.07 | 7.59 % | $ 1.62 B | ||
|
Cullinan Management
CGEM
|
$ 16.04 | 3.42 % | $ 966 M | ||
|
Compugen Ltd.
CGEN
|
$ 2.31 | 0.43 % | $ 216 M | ||
|
Coherus BioSciences
CHRS
|
$ 1.12 | 0.86 % | $ 131 M | ||
|
Celldex Therapeutics
CLDX
|
$ 32.59 | 2.97 % | $ 2.16 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
$ 3.41 | 1.46 % | $ 41.6 M | ||
|
Cellectis S.A.
CLLS
|
$ 1.41 | 0.48 % | $ 141 M | ||
|
Cellectar Biosciences
CLRB
|
$ 1.67 | 0.56 % | $ 4.36 M | ||
|
CNS Pharmaceuticals
CNSP
|
$ 5.3 | 0.7 % | $ 2.35 M | ||
|
Cocrystal Pharma
COCP
|
$ 1.11 | 1.72 % | $ 12.5 M | ||
|
Collegium Pharmaceutical
COLL
|
$ 21.87 | 0.05 % | $ 692 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
$ 122.03 | 4.99 % | $ 12.7 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 5.85 | 0.16 % | $ 77.9 M | ||
|
Cardiff Oncology
CRDF
|
$ 1.14 | 1.79 % | $ 76.2 M | ||
|
Curis
CRIS
|
$ 0.79 | 0.1 % | $ 10.4 M | ||
|
CorMedix
CRMD
|
$ 7.26 | 0.97 % | $ 523 K | ||
|
CRISPR Therapeutics AG
CRSP
|
$ 57.34 | 3.45 % | $ 5.16 B | ||
|
Corvus Pharmaceuticals
CRVS
|
$ 10.74 | 0.09 % | $ 848 M | ||
|
Champions Oncology
CSBR
|
$ 4.97 | 0.61 % | $ 68.7 M | ||
|
CytomX Therapeutics
CTMX
|
$ 2.58 | 0.78 % | $ 356 M | ||
|
Citius Pharmaceuticals
CTXR
|
$ 0.52 | 0.4 % | $ 5.75 M | ||
|
Cue Biopharma
CUE
|
$ 24.36 | 1.27 % | $ 2.31 B | ||
|
CEL-SCI Corporation
CVM
|
$ 2.42 | 4.76 % | $ 19.4 M | ||
|
Cytokinetics, Incorporated
CYTK
|
$ 62.7 | 0.2 % | $ 7.53 M | ||
|
Daré Bioscience
DARE
|
$ 0.84 | 0.04 % | $ 9.39 M | ||
|
DBV Technologies S.A.
DBVT
|
$ 10.44 | 0.47 % | $ 1.46 B | ||
|
DiaMedica Therapeutics
DMAC
|
$ 8.42 | 2.31 % | $ 396 M | ||
|
Denali Therapeutics
DNLI
|
$ 19.91 | 0.41 % | $ 3.44 B |